+Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease
Total number of +securities to be quoted
ASX +security
Number of +securities to
code
Security description
be quoted
Issue date
UBI
CHESS DEPOSITARY INTERESTS 1:1
4,166
14/12/2018
Refer to next page for full details of the announcement
Application for quotation of +securities
1 / 6
Application for quotation of +securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
UNIVERSAL BIOSENSORS INC.
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2
Registered number type
Registration number
ARBN
121559993
1.3
ASX issuer code
UBI
1.4 The announcement is
New announcement
1.5
Date of this announcement
12/11/2021
Application for quotation of +securities
2 / 6
Application for quotation of +securities
Part 2 - Type of Issue
For personal use only
2.1 The +securities to be quoted are:
+Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease
2.2 The +securities to be quoted are:
Additional +securities in a class that is already quoted on ASX ("existing class")
Application for quotation of +securities
3 / 6
Application for quotation of +securities
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
For personal use only
Additional +securities to be quoted in an existing class as a result of transfer restrictions ceasing on an existing class
FROM (Existing Class)
ASX +security code and description
UBIAC : COMMON STOCK
TO (Existing Class)
ASX +security code and description
UBI : CHESS DEPOSITARY INTERESTS 1:1
Please state the number of +securities previously issued under the
And the date the restrictions on
+employee incentive scheme where the restrictions on transfer have ceased
transfer have ceased or will cease
or are about to cease
4,166
11/11/2021
Issue date
14/12/2018
Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
Application for quotation of +securities
4 / 6
Application for quotation of +securities
Issue details
For personal use only
Number of +securities to be quoted
4,166
Are the +securities being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
Conversion of 4,166 restricted shares (UBIAC) into shares of common stock (UBI)
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted
0.000000
Any other information the entity wishes to provide about the +securities to be quoted
Application for quotation of +securities
5 / 6
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Universal Biosensors Inc. published this content on 12 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2021 05:46:09 UTC.
Universal Biosensors, Inc. is a biosensor company. The Company is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, womenâs health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.